Weight-Loss Drugs May Spur Next Major Mass Tort
What can manufacturers of glucagon-like peptide-1 receptor, or GLP-1, weight-loss drugs learn from America's unique mass tort litigation history and how they can successfully defend themselves in future litigation?...To view the full article, register now.
Already a subscriber? Click here to view full article